Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on multiple sclerosis and other autoimmune disorders

NCT ID NCT07337785

Recruiting now Disease control Sponsor: Daishi Tian Source: ClinicalTrials.gov ↗

First seen Jan 14, 2026 · Last updated May 05, 2026 · Updated 13 times

Summary

This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and autoimmune encephalitis. The main goals are to check if the treatment is safe and to see how well it works. About 24 to 36 adults aged 18 to 70 will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING OR REFRACTORY MULTIPLE SCLEROSIS (MS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430000, China

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

AUTOIMMUNE ENCEPHALITIS (AE) CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) MYASTHENIA GRAVIS (MG) RELAPSING OR REFRACTORY MULTIPLE SCLEROSIS (MS)